Oncology News | pharmaphorum

News

Update: Daiichi Sankyo says Plexxikon R&D unit will close do...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D

News

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea

News

BMS cuts $3.15bn deal with Century for cancer cell therapies

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company's pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by li

News

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for

News

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

News

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status.

Update: Daiichi Sankyo says Plexxikon R&D unit will close do...

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

BMS cuts $3.15bn deal with Century for cancer cell therapies

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Roivant joins RNA splicing push with Eisai deal

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks